Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Incoming CDC director predicts 100,000 deaths in next month

In less than a year, Covid-19 has killed almost 400,000 Americans.

And in just the next month, another 100,000 lives could be lost to the disease, the incoming director of the US Centers For Disease Control and Prevention said.

“By the middle of February, we expect half a million deaths in this country,” Dr. Rochelle Walensky told CBS’ “Face the Nation” on Sunday.
“That doesn’t speak to the tens of thousands of people who are living with a yet uncharacterized syndrome after they’ve recovered,” said Walensky, who was chief of infectious diseases at Massachusetts General Hospital before President-elect Joe Biden picked her to lead the CDC.

Source: CDC

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!